Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of TAK-881 in primary immunodeficiency diseases
2023-505946-24-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of TAK-881 in Immunogenetic disorder, sponsored by Takeda. Primary endpoints: Occurrence of treatment-emergent adverse events and Infusion modifications due to TAK-881-related TEAEs. Planned start May 2025; status: authorised.
02
Drugs
TAK-881
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2023-505946-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505946-24-00.